针对肿瘤转移和肿瘤干细胞的新药物研究和治疗策略。

IF 4.8 2区 医学 Q1 PHARMACOLOGY & PHARMACY
Frontiers in Pharmacology Pub Date : 2025-09-16 eCollection Date: 2025-01-01 DOI:10.3389/fphar.2025.1643183
Sicong Xie, Zhiyi Zhou, Yu Zheng, Chenshuo Yu, Weihan Kong, Yushan Chen, Wenzhe Si, Fei Zhou, Zixuan Yang, Ruoxuan Ni, Cheng Chang, Yang Zhang
{"title":"针对肿瘤转移和肿瘤干细胞的新药物研究和治疗策略。","authors":"Sicong Xie, Zhiyi Zhou, Yu Zheng, Chenshuo Yu, Weihan Kong, Yushan Chen, Wenzhe Si, Fei Zhou, Zixuan Yang, Ruoxuan Ni, Cheng Chang, Yang Zhang","doi":"10.3389/fphar.2025.1643183","DOIUrl":null,"url":null,"abstract":"<p><p>Cancer metastasis and stem cells (CSCs) drive resistance and most cancer deaths. Novel agents like Thiolatia (PSMD14 inhibitor) suppress metastasis and enhance chemotherapy efficacy. Sulfarotene targets tumor-repopulating cells in liver cancer with low toxicity. PTC 209 utilizes the high affinity of modified hyaluronic acid nanoparticles for colorectal cancer to reverse CSC stemness in colorectal cancer. Platinum hybrids (HY1-Pt, Salvigenin-Pt) overcome resistance through dual mechanisms. Natural compound Cantharidin inhibits metastasis but requires toxicity optimization. These strategies emphasize specificity, nanodelivery, and combination therapies to reduce toxicity and resistance, highlighting precision oncology potential. Clinical validation remains critical for translation.</p>","PeriodicalId":12491,"journal":{"name":"Frontiers in Pharmacology","volume":"16 ","pages":"1643183"},"PeriodicalIF":4.8000,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12481903/pdf/","citationCount":"0","resultStr":"{\"title\":\"Novel drug research and therapeutic strategies targeting tumor metastasis and cancer stem cells.\",\"authors\":\"Sicong Xie, Zhiyi Zhou, Yu Zheng, Chenshuo Yu, Weihan Kong, Yushan Chen, Wenzhe Si, Fei Zhou, Zixuan Yang, Ruoxuan Ni, Cheng Chang, Yang Zhang\",\"doi\":\"10.3389/fphar.2025.1643183\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Cancer metastasis and stem cells (CSCs) drive resistance and most cancer deaths. Novel agents like Thiolatia (PSMD14 inhibitor) suppress metastasis and enhance chemotherapy efficacy. Sulfarotene targets tumor-repopulating cells in liver cancer with low toxicity. PTC 209 utilizes the high affinity of modified hyaluronic acid nanoparticles for colorectal cancer to reverse CSC stemness in colorectal cancer. Platinum hybrids (HY1-Pt, Salvigenin-Pt) overcome resistance through dual mechanisms. Natural compound Cantharidin inhibits metastasis but requires toxicity optimization. These strategies emphasize specificity, nanodelivery, and combination therapies to reduce toxicity and resistance, highlighting precision oncology potential. Clinical validation remains critical for translation.</p>\",\"PeriodicalId\":12491,\"journal\":{\"name\":\"Frontiers in Pharmacology\",\"volume\":\"16 \",\"pages\":\"1643183\"},\"PeriodicalIF\":4.8000,\"publicationDate\":\"2025-09-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12481903/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Frontiers in Pharmacology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3389/fphar.2025.1643183\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fphar.2025.1643183","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

癌症转移和干细胞(CSCs)驱动耐药性和大多数癌症死亡。新型药物如Thiolatia (PSMD14抑制剂)抑制肿瘤转移,提高化疗效果。磺胺罗芬低毒性靶向肝癌肿瘤再生细胞。PTC 209利用修饰透明质酸纳米颗粒对结直肠癌的高亲和力来逆转结直肠癌的CSC干细胞。铂杂化物(HY1-Pt, Salvigenin-Pt)通过双重机制克服抗性。天然化合物斑蝥素抑制肿瘤转移,但需要毒性优化。这些策略强调特异性、纳米递送和联合治疗,以减少毒性和耐药性,突出了精确肿瘤学的潜力。临床验证仍然是翻译的关键。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Novel drug research and therapeutic strategies targeting tumor metastasis and cancer stem cells.

Cancer metastasis and stem cells (CSCs) drive resistance and most cancer deaths. Novel agents like Thiolatia (PSMD14 inhibitor) suppress metastasis and enhance chemotherapy efficacy. Sulfarotene targets tumor-repopulating cells in liver cancer with low toxicity. PTC 209 utilizes the high affinity of modified hyaluronic acid nanoparticles for colorectal cancer to reverse CSC stemness in colorectal cancer. Platinum hybrids (HY1-Pt, Salvigenin-Pt) overcome resistance through dual mechanisms. Natural compound Cantharidin inhibits metastasis but requires toxicity optimization. These strategies emphasize specificity, nanodelivery, and combination therapies to reduce toxicity and resistance, highlighting precision oncology potential. Clinical validation remains critical for translation.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Frontiers in Pharmacology
Frontiers in Pharmacology PHARMACOLOGY & PHARMACY-
CiteScore
7.80
自引率
8.90%
发文量
5163
审稿时长
14 weeks
期刊介绍: Frontiers in Pharmacology is a leading journal in its field, publishing rigorously peer-reviewed research across disciplines, including basic and clinical pharmacology, medicinal chemistry, pharmacy and toxicology. Field Chief Editor Heike Wulff at UC Davis is supported by an outstanding Editorial Board of international researchers. This multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信